Atai Life Sciences N.V.

ATAI Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, is a clinical-stage biopharmaceutical company specializing in developing therapeutic candidates for mental health disorders. Its products include formulations of ketamine, ibogaine, N-acetylcysteine, and other compounds for the treatment of conditions such as treatment-resistant depression, cognitive impairment associated with schizophrenia, opioid use disorder, generalized anxiety disorder, and mild traumatic brain injuries. The company focuses on advancing these candidates through clinical trials and eventual commercialization to address unmet medical needs in the mental health space.

Products

• PCN-101 (R-ketamine)

• RL-007 (cholinergic, glutamatergic, and GABA-B receptor modulator)

• DMX-1002 (ibogaine)

• GRX-917 (deuterated version of etifoxine)

• NN-101 (N-acetylcysteine)

• VLS-01 (N,N-dimethyltryptamine)

• EMP-01 (3,4-methyl enedioxy methamphetamine)

• RLS-01 (Salvinorin A)

• KUR-101 (deuterated mitragynine)

• DMX-1001 (noribogaine)